<DOC>
	<DOC>NCT02447302</DOC>
	<brief_summary>The purpose of this study is to determine whether APD334 is a safe and effective treatment for ulcerative colitis.</brief_summary>
	<brief_title>Safety and Efficacy of APD334 in Patients With Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Moderately to severely active ulcerative colitis defined as a 3component Mayo Clinic score Evidence of colonic ulcerative colitis activity on endoscopy Within 30 days prior to randomization, receipt of any of the following for the treatment of underlying disease: Nonbiologic therapies (eg, cyclosporine, tacrolimus, tofacitinib, thalidomide), a nonbiologic investigational therapy or an approved nonbiologic therapy in an investigational protocol Within 60 days prior to randomization, receipt of any of the following: Infliximab, adalimumab, golimumab, certolizumab or any other investigational or approved biologic agent Any prior exposure to natalizumab, efalizumab, or rituximab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>